Advertisement

Advertisement
Solid Tumors

Stereotactic Ablative Radiotherapy May Improve Outcomes in Some Patients With Oligometastatic Tumors

In patients with a controlled primary tumor and up to 5 oligometastatic lesions, delivering stereotactic ablative radiotherapy was associated...

Issues in Oncology

Should Oncologists Recommend Cannabis?

A recent survey of 400 clinical oncologists found that 80% discuss the use of medical cannabis with their patients, and although nearly 50% recommend it...

CNS Cancers

Hippocampus-Sparing Whole-Brain Radiotherapy and Neurocognitive Function in Patients With Brain Metastases

Analysis of a phase III trial has confirmed that conformal avoidance of the hippocampal dentate gyrus using intensity-modulated radiotherapy...


Advertisement
Skin Cancer

Using Tumor‑Infiltrating Lymphocytes to Treat Metastatic Melanoma

Steven A. Rosenberg, MD, PhD, Chief of Surgery at the National Cancer Institute (NCI), began his pioneering research in adoptive cell transfer using interleukin...

Kidney Cancer

Progress Made in Identifying Gene-Signature Biomarkers in Renal Cell Carcinoma

A new analysis of the phase III IMmotion151 trial identified gene signatures in renal cell carcinoma that correlate with improved progression-free survival...

 

Advertisement




More Top Stories

Breast Cancer
Issues in Oncology

Laura S. Dominici, MD, on Young Women With Breast Cancer: Local Therapy and Quality of Life

Skin Cancer

Encorafenib and Binimetinib: A New Benchmark in Metastatic Melanoma Therapy?

IN JULY 2018, the U.S. Food and Drug Administration (FDA) approved the combination of the oral BRAF inhibitor encorafenib (Braftovi) and the oral MEK inhibitor binimetinib (Mektovi) for BRAF V600E– or V600K– positive metastatic melanoma. The FDA approval was based on the results of the COLUMBUS...

Advertisement

ECHELON-2: Brentuximab Vedotin Plus Chemotherapy in CD30-Positive Peripheral T-Cell Lymphoma

As reported by Horwitz et al in The Lancet, the phase III ECHELON-2 trial showed that brentuximab vedotin (Adcetris) plus cyclophosphamide, doxorubicin, and prednisone (CHP) improved progression-free and overall survival vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in...

Leukemia

Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study

Skin Cancer

The Skin Cancer Foundation Raises $600,000 at Gala

The Skin Cancer Foundation recently held its 22nd annual Gala at The Plaza Hotel in New York. The Champions for Change Gala is the Foundation’s signature fundraising event, and $600,000 was raised to support the organization’s educational campaigns, community programs, and research initiatives....

Supportive Care
Palliative Care

Artificial Intelligence–Based Smartphone App Decreases Pain and Reduces Inpatient Hospitalizations in Patients With Cancer

A smartphone application utilizing elements of artificial intelligence was associated with improved cancer pain outcomes and a significant reduction in pain-related hospital admissions, according to data presented at the 2018 Palliative and Supportive Care in Oncology Symposium.1 Results of the...

RSNA 2018: Mammography Screening Beyond Age 75

Women aged 75 years and older may benefit from continued screening mammograms because of the comparatively high incidence of breast cancer found in this age group, according to a study presented at the Annual Meeting of the Radiological Society of North America (RSNA) (Abstract SSA01-04)....

Breast Cancer
Immunotherapy

Hope S. Rugo, MD, on Immunotherapy for Breast Cancer: Expert Perspective

Genomics/Genetics

Role of Genomic Profiling in Younger Patients With Cancer

Although overall cancer survival rates continue to improve among all age groups in the United States—there are currently an estimated 15.5 million cancer survivors, and that number is expected to increase to 20.3 million by 20261—survival rates for adolescents and young adults with cancer (AYAs)...

Advertisement

RSNA 2018: Breast Cancer Risk-Based Mammography Screening in Younger Women

A new, large-scale study of more than 5 million mammograms found that annual mammography screening beginning at age 30 may benefit women with at least 1 of 3 specific risk factors: dense breasts, a personal history of breast cancer, or a family history of breast cancer. The study was presented at...